5 Amino 1MQ: Research, Purity Testing and COA

5 Amino 1MQ isn't a peptide. It's a methylated quinolinium salt: no amino acids, no peptide bonds, and a cation weighing roughly 159 g/mol. Yet a large share of the catalogs listing it file it under peptides anyway, which tells you something useful about how carefully the rest of that listing was checked.

The purity percentage printed at the top of a certificate of analysis is usually the least informative number on the page.

What is 5 amino 1mq?

5 Amino 1MQ (5-amino-1-methylquinolinium) is a membrane-permeable small-molecule inhibitor of nicotinamide N-methyltransferase, or NNMT, the enzyme that methylates nicotinamide and diverts it away from the NAD+ salvage pathway. It is a research-use-only compound with no published human clinical trials. Any batch should be verified against a lot-matched certificate of analysis before laboratory use.

The common oversimplification is that a high purity figure settles the quality question. It doesn't. An HPLC report can read 99.2% while confirming nothing about whether the material in the vial is actually 5-amino-1-methylquinolinium, because purity and identity are measured on different instruments. What follows covers the NNMT mechanism in detail, the current state of 5-amino-1mq research including the human trial gap, and how to read a 5-amino-1mq certificate of analysis line by line.

How NNMT inhibition rearranges methyl and NAD+ traffic

NNMT does one job. It transfers a methyl group from SAM (S-adenosylmethionine, the cell's universal methyl donor) onto nicotinamide, producing 1-methylnicotinamide (1-MNA) and SAH (S-adenosylhomocysteine). That single reaction carries two downstream consequences, and 5 Amino 1MQ is studied because it interrupts both.

First, nicotinamide is the substrate of the NAD+ salvage pathway, the recycling route that regenerates nicotinamide adenine dinucleotide, the coenzyme that redox reactions and sirtuin enzymes depend on. Once nicotinamide is methylated, it's committed to excretion rather than salvage. Second, every methyl transfer consumes SAM and generates SAH, so sustained NNMT activity depresses the SAM:SAH ratio that governs methylation capacity across the cell. Research has reported elevated NNMT expression in white adipose tissue and liver in metabolic disease models, which is precisely why the enzyme became a target.

What separated this compound from earlier NNMT inhibitors is permeability. Bisubstrate analogs assembled from SAM and nicotinamide fragments inhibited the isolated enzyme well, but were too large and too polar to cross a cell membrane, so they collapsed the moment anyone moved from a cuvette to intact cells. 5 Amino 1MQ is small, permanently cationic and membrane-permeable, which is why it sits among oral research compounds rather than injectable material.

Sourcing is where experiments actually fail.

What the published research shows, and where the evidence stops

The 5-amino-1mq research base is preclinical. Published work on membrane-permeable NNMT inhibitors, including research led by Neelakantan and colleagues in Biochemical Pharmacology, reported that administering this inhibitor class to diet-induced obese mice reduced body weight and adipose tissue mass without a matching drop in food intake, alongside reduced NNMT activity in fat tissue. Cell-based work has examined the same enzyme in adipocytes, hepatocytes and several cancer lines where NNMT is overexpressed.

Now the part most pages skip. There are no published, peer-reviewed human clinical trial results for 5 Amino 1MQ. Searches for 5 amino 1mq human trials surface a great deal of marketing prose and no trial reports, because the compound has not completed a registered clinical trial. It carries no FDA approval for any indication, in any population, at any quantity. Rodent adipose data is a hypothesis generator, not evidence of a human effect, and the distance between those two things is where most writing on this compound goes wrong.

Everything here is laboratory documentation. 5 Amino 1MQ is supplied for in vitro and laboratory research use only and is not for human or veterinary consumption. If curiosity about this compound started with an animal's health, talk to your veterinarian about that, because a research catalog is not the place for it.

Hedged claims should stay hedged. Research suggests NNMT inhibition alters adipocyte energy handling in rodent models.

Reading a 5 amino 1mq certificate of analysis line by line

A certificate of analysis is a batch document, not a product document. It describes one lot, tested on one date, and it's only useful if the lot number printed on it matches the lot number on the vial in your hand. That cross-check fails more often than anyone admits, and a mismatched 5-amino-1mq coa is functionally a blank page.

A complete 5-amino-1mq certificate of analysis contains:

• Lot or batch number and date of analysis, matching the container label exactly
• Identity by mass spectrometry, confirming the expected molecular ion for the 5-amino-1-methylquinolinium cation
• Structural confirmation by NMR, proton and ideally carbon, showing the methyl and amino substitution pattern
• Purity by HPLC, with column, mobile phase, gradient and detection wavelength stated
• Water content by Karl Fischer titration, since hygroscopic salts carry water that inflates apparent mass
• Residual solvents by GC and elemental impurities by ICP-MS
• Appearance, storage conditions, and the laboratory or analyst who signed it

So what does a purity number actually prove? Less than you'd think. HPLC purity is reported as area percent: the share of total UV absorbance the detector saw at one wavelength that belongs to your peak. Anything that doesn't absorb at that wavelength is invisible to it. Inorganic salts, residual water and non-chromophoric residues never appear. A 99% area-percent figure with no mass spectrum, no NMR and no Karl Fischer value is a statement about one detector's field of view, not about the contents of the vial. Purity without identity is the single most common documentation gap we see, and it's why our published certificates of analysis are lot-matched and posted alongside each listing, including 5-Amino-1MQ.

Documentation tiers and what each one actually proves

Not every certificate carries the same evidentiary weight, and the difference matters when an unexplained result forces you to rule out the material itself. This table maps what each documentation tier verifies, what it leaves open, and whether it's defensible for laboratory work.

What If: Verification Scenarios in the Lab

What if my 5 amino 1mq certificate lists purity but no mass spectrum?

Request the mass spectrometry data for that lot before the material enters any experiment. Without a confirmed molecular ion, you have a clean chromatogram of an unidentified substance, which is a different problem from an impure one. Suppliers who run identity testing keep those files on hand and can produce them within a day; suppliers who can't produce them generally never ran the analysis.

What if the lot number on the vial doesn't match the certificate?

Stop and contact the supplier before opening the container. A certificate describes one synthesis batch tested on one date, so a mismatch means the document in front of you describes different material entirely.

What if the powder looks different from the appearance stated on the report?

Photograph it, don't use it, and raise it with the supplier. Quinolinium iodide salts can darken with light exposure, and hygroscopic material can clump after humidity ingress during transit, so a deviation from the stated appearance is a real signal about handling history rather than a cosmetic quibble. Neither change is detectable by purity testing you can perform at the bench.

What if my results don't replicate a published rodent finding?

Rule out the material before rethinking the hypothesis. Differences in salt form, water content and actual mass of active cation shift effective concentration substantially, and a batch carrying several percent water by Karl Fischer delivers less compound per weighed milligram than the label implies. Check the certificate values first, then vehicle, then model.

The unglamorous truth about purity claims on research compounds

Here's the honest answer: most purity numbers advertised for this compound are copied, not measured. A number printed in a product description with no accompanying chromatogram, no lot reference and no analysing laboratory carries zero evidentiary value, and it appears identically across dozens of unrelated sites because it was never generated by anyone selling it. The evidence is clear on what fixes this. Demand the raw instrument output, matched to the lot in your hand, from a laboratory that doesn't share ownership with the seller. Everything else is decoration. Our full research catalog is documented on that standard for exactly this reason.

5 Amino 1MQ occupies an awkward and honest position: a genuinely interesting enzymology target with a real preclinical literature behind it, and almost nothing else. The temptation across this corner of the market is to fill that gap with confident language about metabolic outcomes nobody has measured in people. Resisting that is what separates research documentation from sales copy. If you take one habit away from this, make it the lot-number cross-check, because a compound you can't identify produces data you can't defend, no matter how clean the chromatogram looks.

How should lyophilized 5-amino-1MQ be stored in a research facility?

Lyophilized small-molecule salts of this type are generally stored cold, dry, and dark. Freezer storage at roughly −20 °C is the common default for long-term holding, with refrigeration acceptable for shorter intervals; the controlling variables are moisture ingress, temperature cycling, and light exposure. Quinolinium salts can be hygroscopic, so vials are typically kept sealed with desiccant and allowed to equilibrate to room temperature before opening, which limits condensation on cold powder. Repeated warming and cooling is the most avoidable source of avoidable loss.

Solid-state material is substantially more stable than material held in solution, where hydrolytic and oxidative pathways operate faster and where storage questions become time-limited rather than open-ended — the subject of degradation in reconstituted material. Facilities that track stability formally will re-run identity and purity analytics after extended storage rather than relying on the original certificate indefinitely, since a COA describes the material as tested on a given date.

General handling considerations for lyophilized powder in laboratory settings are covered separately, and recurring storage and labeling questions appear in the compound FAQ. All material remains for research use only, not for human consumption.

What is the regulatory status of 5-amino-1MQ for laboratory purchase?

5-Amino-1MQ has no approved therapeutic indication in the United States or the European Union. It is not a dietary supplement ingredient, not a compounding-eligible drug substance, and not an approved biologic; it circulates as a research chemical sold for in vitro and preclinical laboratory use. That status shapes how it may legitimately be described in catalogs, invoices, and institutional purchasing records — as a reference compound for enzyme and cell studies, with no efficacy or safety representations attached.

Practically, this means buyers should expect research-use-only labeling, a certificate of analysis tied to a specific lot, and supplier documentation that does not make therapeutic claims. Import and customs handling vary by jurisdiction, and institutional chemical hygiene plans typically require a safety data sheet on file regardless of regulatory classification. Laboratories sometimes conflate "not scheduled" with "approved"; those are different statements, and only the first is true here.

Buyers reviewing compliance questions usually start with the legal purchase and research framework, then confirm the FDA approval status of this research compound. Sourcing considerations, including lot documentation expectations, are discussed under availability for research purchase. Nothing here is a recommendation for human use.

Which biomarkers do laboratories track in NNMT inhibition experiments?

The most direct readout is the enzyme's own product: 1-methylnicotinamide, typically quantified in cells, tissue, plasma, or urine by LC-MS/MS against a stable-isotope internal standard. A fall in 1-methylnicotinamide relative to nicotinamide is the clearest evidence that target engagement occurred, and it is far more specific than any downstream phenotype. Secondary measures include NAD⁺ and NADH pools, the SAM/SAH ratio as an index of methylation capacity, and nicotinamide itself.

Beyond the immediate pathway, studies commonly add transcriptional panels covering lipogenic, lipolytic, and mitochondrial biogenesis genes, plus protein-level confirmation by Western blot. In whole-animal work, body composition, tissue weights, and circulating lipid and glucose chemistries are standard, though these are phenotypic endpoints several steps removed from the enzyme and are easily confounded by feeding behavior and housing conditions.

Laboratories designing panels often cross-reference metabolic research tracking biomarkers with gene expression and metabolic impact, and use in vitro cellular metabolic studies to validate assay sensitivity before scaling. Comparative baseline-and-endpoint analytics are discussed under laboratory panels before and after. Target-engagement markers should always anchor the interpretation.

What exactly is 5-amino-1MQ, and where did this compound come from?

5-Amino-1-methylquinolinium (5-amino-1MQ) is a small quinolinium salt, not a peptide, developed as a cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT). Its origin sits in metabolic enzymology rather than hormone pharmacology. NNMT transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide and consuming methyl donor capacity, and interest in blocking that reaction grew after antisense knockdown of NNMT in adipose tissue was reported to protect mice against diet-induced obesity (PubMed (PubMed PMID 24717514)). Medicinal chemistry efforts then produced small-molecule, membrane-permeable NNMT inhibitors in the quinolinium series, described in a 2017 report in which such compounds were tested in high-fat-diet mouse models (PubMed (PubMed PMID 28322736)).

Because the scaffold resembles the enzyme's own substrate and product, selectivity against other methyltransferases has been a recurring question in the literature. The research history of this compound therefore runs parallel to the broader story of NNMT as a metabolic target, and the mechanism studies on NNMT inhibition remain the primary evidence base. For laboratories comparing what exists in rodents versus people, the distinction between those two literatures is covered separately under animal and human research. All material discussed here is for in vitro and preclinical laboratory use only.

How does NNMT inhibition affect adipocyte biology in preclinical models?

White adipocytes express NNMT at relatively high levels, which is why adipose tissue became the first focus of NNMT research. The working hypothesis in the published literature is that high NNMT activity acts as a sink for both methyl groups and nicotinamide, the salvage precursor for NAD⁺. Reducing that sink is proposed to raise intracellular nicotinamide availability and shift polyamine flux, which in turn has been linked to altered lipogenic and lipolytic gene expression in cultured adipocytes. Adipose-specific knockdown work reported protection against diet-induced obesity in mice (PubMed (PubMed PMID 24717514)), and small-molecule inhibitors were later tested in comparable obesity models (PubMed (PubMed PMID 28322736)).

What these studies do not establish is a complete map from enzyme inhibition to tissue phenotype; several intermediate steps remain inferred rather than demonstrated. Laboratories working on this pathway typically pair whole-animal endpoints with cell-level readouts, which is why adipose tissue biology and in vitro cellular metabolic studies are usually read together. The downstream effects of NNMT inhibition extend beyond lipid handling into methylation-sensitive transcription, and the broader mechanism and results literature summarizes how those threads are currently organized.

Has 5-amino-1MQ been tested in humans, or only in animals?

The substantive published record for 5-amino-1MQ is preclinical: enzyme assays, cultured cell work, and rodent models of diet-induced obesity. Mouse studies using membrane-permeable NNMT inhibitors in this chemical class have been reported (PubMed (PubMed PMID 28322736)), and genetic knockdown studies established the target rationale (PubMed (PubMed PMID 24717514)). There is no body of peer-reviewed, controlled human efficacy data comparable to what exists for approved metabolic drugs, and no completed large-scale human safety program that a buyer can point to.

That gap matters for how laboratory results should be framed. Rodent metabolic phenotypes translate inconsistently, NNMT expression patterns differ across species and tissues, and long-duration safety endpoints have not been characterized in the open literature. Teams evaluating this compound usually review the animal research findings and lab applications first, then check what is registered or anticipated in clinical trial tracking before making claims in a grant or protocol document. Questions about chronic exposure belong under long-term studies, and the formal FDA approval status of this research compound should be stated plainly in any internal documentation: it is not an approved therapeutic.

What is known about half-life, permeability, and absorption in preclinical work?

Pharmacokinetic characterization of 5-amino-1MQ is thinner than its mechanistic characterization. The compound is a permanently charged quaternary quinolinium species, which ordinarily argues against passive membrane crossing; the published interest in this chemical series arose specifically because certain analogs were described as membrane-permeable while retaining NNMT inhibitory activity (PubMed (PubMed PMID 28322736)). How that permeability is achieved — transporter-mediated uptake versus intrinsic physicochemical behavior — is still discussed rather than settled.

For laboratory planning, the practical consequences are that clearance, tissue distribution, and plasma exposure figures reported in rodents should not be extrapolated across species, and that in vitro potency values from isolated enzyme assays frequently diverge from cell-based potency because of uptake limitations. Researchers comparing assay formats often consult the half-life literature alongside bioavailability and absorption science to understand why cell-free IC₅₀ values and cellular EC₅₀ values differ. Timing of downstream readouts — NAD⁺ pools, methylation-sensitive transcripts, lipid endpoints — also depends on how quickly intracellular concentrations rise and fall, a topic treated under effectiveness and timing. Where published numbers do not exist, the honest answer in a methods section is that the parameter is uncharacterized.

How does 5-amino-1MQ compare mechanistically with incretin-class metabolic compounds?

The two categories act on entirely different biology. Incretin-class agents are peptide ligands for G-protein-coupled receptors — GLP-1 and, in dual agonists, GIP receptors — operating upstream at the level of hormone signaling, affecting insulin secretion, gastric motility, and central appetite circuits. 5-Amino-1MQ is a small molecule that binds an intracellular enzyme, NNMT, and alters methyl-group and nicotinamide flux inside the cell. One is receptor pharmacology; the other is metabolic enzymology.

That distinction has consequences for experimental design. Receptor agonists are studied with binding assays, cAMP accumulation, and β-arrestin recruitment; NNMT inhibition is assessed with enzyme kinetics, 1-methylnicotinamide quantitation by LC-MS, NAD⁺/NADH ratios, and methylation-sensitive transcriptional readouts. Published NNMT inhibitor work in rodent obesity models exists (PubMed (PubMed PMID 28322736)), but it is not head-to-head data against incretin agents, and no such comparison should be implied.

Researchers mapping these differences often read the mechanistic comparison with incretin-type compounds alongside the class-level alternative discussion, the broader comparative studies and evidence review, and the survey of related research options.

What does the aging and stem cell literature report about NNMT inhibition?

NNMT sits at a junction between methyl-donor availability and NAD⁺ salvage, both of which decline or shift with age in multiple tissues, so the enzyme attracted attention from aging researchers independently of the obesity work. Published investigation in this area has examined aged skeletal muscle and its resident satellite cell population, where methylation capacity and NAD⁺ status influence quiescence, activation, and regenerative response after injury. Specific effect sizes vary across the primary reports, and anyone citing this line of work should read the original papers rather than secondary summaries, since model age, injury method, and measurement window strongly influence outcomes.

The mechanistic rationale is consistent with the broader NNMT literature, where genetic knockdown established metabolic consequences in vivo (PubMed (PubMed PMID 24717514)). What remains unresolved is whether enzymatic inhibition reproduces knockdown phenotypes across tissues, and whether effects observed in muscle generalize to other progenitor populations.

Researchers approaching this angle typically review stem cell activation research alongside animal research findings and lab applications, and consult the age-specific research literature and the summarized benefits evidence with appropriate caution about extrapolation. These are preclinical observations, not human outcomes.